Journal of Clinical Endocrinology & Metabolism, Vol 79, 230-232, Copyright © 1994 by Endocrine Society

ARTICLES

Recombinant human insulin-like growth factor-I increases forearm blood flow

KC Copeland and KS Nair
Department of Pediatrics, University of Vermont College of Medicine, Burlington 05405.

Several recent reports have described systemic effects associated with insulin-like growth factor-I (IGF-I) infusions in humans, including dizziness, syncope, unconsciousness, bradycardia, and asystole. Eleven healthy volunteers (10 males and 1 female) underwent brachial arterial and deep forearm venous catheterizations to evaluate the effects of an intraarterial infusion of IGF-I on blood flow. Saline was infused into the brachial artery for 1 h, followed by infusions of recombinant human IGF-I (1.25, then 10 micrograms/kg BW.h) over 2 subsequent 90-min periods. Blood flow across the forearm was determined from dye dilution curves after an infusion of indocyanine green dye (20 mg/h) into the proximal arterial port. The rate of saline infusion had no effect on forearm blood flow. Likewise, the low dose arterial IGF-I infusion had no effect on blood flow, even though deep venous IGF-I concentrations increased slightly (127 +/- 37 to 172 +/- 19 ng/mL; P = NS). The 10 micrograms/kg.h infusion rate increased deep venous IGF-I concentrations approximately 4-fold above control values (477 +/- 80 vs. 150 +/- 27 ng/mL, respectively; P < 0.0001), whereas IGF-I concentrations in the peripheral circulation were increased approximately 2-fold (299 +/- 50 ng/mL) above control values (P < 0.0001). Arteriovenous glucose differences, peripheral glucose concentrations, and binding protein-3 concentrations were not influenced by either dose of IGF-I. The 10 micrograms/kg.h dose of IGF- I was associated with a 68% increase in forearm blood flow (71 +/- 8 vs. 42 +/- 6 mL/min, respectively; P < 0.0004). These data suggest that an intravascular infusion of IGF-I results in significant alterations in regional blood flow, which may be related to the observed physiological effects or side-effects associated with its use.

This article has been cited by other articles:

				S.-J. Kim, M. Abdellatif, S. Koul, and G. J. Crystal Chronic treatment with insulin-like growth factor I enhances myocyte contraction by upregulation of Akt-SERCA2a signaling pathway Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H130 - H135. [Abstract] [Full Text] [PDF]

				G. Li, J.-P. del Rincon, L. A. Jahn, Y. Wu, B. Gaylinn, M. O. Thorner, and Z. Liu Growth Hormone Exerts Acute Vascular Effects Independent of Systemic or Muscle Insulin-like Growth Factor I J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1379 - 1385. [Abstract] [Full Text] [PDF]

				C. Schmid, M. Brandle, C. Zwimpfer, J. Zapf, and P. Wiesli Effect of Thyroxine Replacement on Creatinine, Insulin-Like Growth Factor 1, Acid-Labile Subunit, and Vascular Endothelial Growth Factor Clin. Chem., January 1, 2004; 50(1): 228 - 231. [Full Text] [PDF]

				R. Napoli, V. Guardasole, V. Angelini, F. D'Amico, E. Zarra, M. Matarazzo, and L. Sacca Acute Effects of Growth Hormone on Vascular Function in Human Subjects J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2817 - 2820. [Abstract] [Full Text] [PDF]

				D. von Lewinski, K. Voss, S. Hulsmann, H. Kogler, and B. Pieske Insulin-Like Growth Factor-1 Exerts Ca2+-Dependent Positive Inotropic Effects in Failing Human Myocardium Circ. Res., February 7, 2003; 92(2): 169 - 176. [Abstract] [Full Text] [PDF]

				C. Vecchione, S. Colella, L. Fratta, M. T. Gentile, G. Selvetella, G. Frati, B. Trimarco, and G. Lembo Impaired Insulin-Like Growth Factor I Vasorelaxant Effects in Hypertension Hypertension, June 1, 2001; 37(6): 1480 - 1485. [Abstract] [Full Text] [PDF]

				G. Zhao, R. L. Sutliff, C. S. Weber, J. Wang, J. Lorenz, R. J. Paul, and J. A. Fagin Smooth Muscle-Targeted Overexpression of Insulin-Like Growth Factor I Results in Enhanced Vascular Contractility Endocrinology, February 1, 2001; 142(2): 623 - 632. [Abstract] [Full Text] [PDF]

				D. Li, G. Sweeney, Q. Wang, and A. Klip Participation of PI3K and atypical PKC in Na+-K+-pump stimulation by IGF-I in VSMC Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H2109 - H2116. [Abstract] [Full Text] [PDF]

				M. Y. Donath, G. Sütsch, X.-W. Yan, B. Piva, H.-P. Brunner, Y. Glatz, J. Zapf, F. Follath, E. R. Froesch, and W. Kiowski Acute Cardiovascular Effects of Insulin-Like Growth Factor I in Patients with Chronic Heart Failure J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3177 - 3183. [Abstract] [Full Text]

				D. Hasdai, D. R. Holmes Jr., D. M. Richardson, U. Izhar, and A. Lerman Insulin and IGF-I attenuate the coronary vasoconstrictor effects of endothelin-1 but not of sarafotoxin 6c Cardiovasc Res, September 1, 1998; 39(3): 644 - 650. [Abstract] [Full Text] [PDF]

				M. Pendergrass, E. Fazioni, D. Collins, and R. A. DeFronzo IGF-I increases forearm blood flow without increasing forearm glucose uptake Am J Physiol Endocrinol Metab, August 1, 1998; 275(2): E345 - E350. [Abstract] [Full Text] [PDF]

				D. Hasdai, R. A. Rizza, D. R. Holmes Jr, D. M. Richardson, P. Cohen, and A. Lerman Insulin and Insulin-like Growth Factor-I Cause Coronary Vasorelaxation In Vitro Hypertension, August 1, 1998; 32(2): 228 - 234. [Abstract] [Full Text] [PDF]

				T. M. Abdelbaky, G. B. Brock, and H. Huynh Improvement of Erectile Function in Diabetic Rats by Insulin: Possible Role of the Insulin-Like Growth Factor System Endocrinology, July 1, 1998; 139(7): 3143 - 3147. [Abstract] [Full Text] [PDF]

				A. Cittadini, Y. Ishiguro, H. Stromer, M. Spindler, A. C. Moses, R. Clark, P. S. Douglas, J. S. Ingwall, and J. P. Morgan Insulin-like Growth Factor-1 but Not Growth Hormone Augments Mammalian Myocardial Contractility by Sensitizing the Myofilament to Ca2+ Through a Wortmannin-Sensitive Pathway : Studies in Rat and Ferret Isolated Muscles Circ. Res., June 13, 1998; 83(1): 50 - 59. [Abstract] [Full Text] [PDF]

				G. Johannsson, P. Marin, L. Lonn, M. Ottosson, K. Stenlof, P. Bjorntorp, L. Sjostrom, and B.-A. Bengtsson Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 727 - 734. [Abstract] [Full Text] [PDF]

				J. R. Sowers Insulin and Insulin-Like Growth Factor in Normal and Pathological Cardiovascular Physiology Hypertension, March 1, 1997; 29(3): 691 - 699. [Full Text]

				R. L. Duerr, M. D. McKirnan, R. D. Gim, R. G. Clark, K. R. Chien, and J. Ross Jr Cardiovascular Effects of Insulin-Like Growth Factor-1 and Growth Hormone in Chronic Left Ventricular Failure in the Rat Circulation, June 15, 1996; 93(12): 2188 - 2196. [Abstract] [Full Text]

				J. R. Sowers and M. Epstein Diabetes Mellitus and Associated Hypertension, Vascular Disease, and Nephropathy : An Update Hypertension, December 1, 1995; 26(6): 869 - 879. [Abstract] [Full Text]